|
1
|
Davis AP, Kao SC, Clarke SJ, Boyer M and
Pavlakis N: Emerging biological therapies for the treatment of
malignant pleural mesothelioma. Expert Opin Emerg Drugs.
26:179–192. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Parker C and Neville E: Lung cancer
* 8: Management of malignant mesothelioma. Thorax.
58:809–813. 2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Husain AN, Colby TV, Ordóñez NG, Allen TC,
Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S,
et al: Guidelines for pathologic diagnosis of malignant
mesothelioma 2017 update of the consensus statement from the
International mesothelioma interest group. Arch Pathol Lab Med.
142:89–108. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Baas P, Scherpereel A, Nowak AK, Fujimoto
N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et
al: First-line nivolumab plus ipilimumab in unresectable malignant
pleural mesothelioma (CheckMate 743): A multicentre, randomised,
open-label, phase 3 trial. Lancet. 397:375–386. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Scherpereel A, Antonia S, Bautista Y,
Grossi F, Kowalski D, Zalcman G, Nowak A, Fujimoto N, Peters S,
Tsao A, et al: First-line nivolumab (NIVO) plus ipilimumab (IPI)
versus chemotherapy (chemo) for the treatment of unresectable
malignant pleural mesothelioma (MPM): Patient-reported outcomes
(PROs) from CheckMate 743. Ann Oncol. 31 (Suppl 7)(S1441)2020.
|
|
6
|
Wright K: FDA approves nivolumab plus
ipilimumab for previously untreated unresectable malignant pleural
mesothelioma. Oncology (Williston Park). 34:502–503.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Peters S, Scherpereel A, Cornelissen R,
Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S,
Baas P, et al: First-line nivolumab (NIVO) plus ipilimumab (IPI) vs
chemotherapy (chemo) in patients (pts) with unresectable malignant
pleural mesothelioma (MPM): 3-year update from CheckMate 743. Ann
Oncol. 32 (Suppl 5):S1283–S1346. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Forde PM, Sun Z, Anagnostou V, Kindler HL,
Purcell WT, Goulart BHL, Dudek AZ, Borghaei H, Brahmer JR and
Ramalingam SS: PrE0505: Phase II multicenter study of anti-PD-L1,
durvalumab, in combination with cisplatin and pemetrexed for the
first-line treatment of unresectable malignant pleural mesothelioma
(MPM)-A PrECOG LLC study. J Clin Oncol. 38 (Suppl
15)(S9003)2020.
|
|
9
|
Nowak AK, Lesterhuis WJ, Kok PS, Brown C,
Hughes BG, Karikios DJ, John T, Kao SC, Leslie C, Cook AM, et al:
Durvalumab with first-line chemotherapy in previously untreated
malignant pleural mesothelioma (DREAM): A multicentre, single-arm,
phase 2 trial with a safety run-in. Lancet Oncol. 21:1213–1223.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Forde PM, Nowak AK, Kok PS, Brown C, Sun
Z, Anagnostou V, O'Byrne KJ, Yip S, Cook A, Lesterhuis WJ, et al:
DREAM3R: Durvalumab with chemotherapy as first-line treatment in
advanced pleural mesothelioma-a phase 3 randomized trial. J Chin
Oncol. 39(TPS8586)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Quispel-Janssen J, van der Noort V, de
Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K,
Schouten R, Schunselaar L, Disselhorst M, et al: Programmed Death 1
Blockade with nivolumab in patients with recurrent malignant
pleural mesothelioma. J Thorac Oncol. 13:1569–1576. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Okada M, Kijima T, Aoe K, Kato T, Fujimoto
N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, et al:
Clinical efficacy and safety of nivolumab: Results of a
multicenter, open-label, single-arm, Japanese phase II study in
malignant pleural mesothelioma (MERIT). Clin Cancer Res.
18:5485–5492. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hayashi H, Okada M, Kijima T, Aoe K, Kato
T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, et al:
Three-year follow-up results of the MERIT trial: A Japanese phase
II study of nivolumab in malignant pleural mesothelioma. Ann Oncol.
31(S1076)2020.
|
|
14
|
Fennell DA, Kirkpatrick E, Cozens K, Nye
M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J, et
al: CONFIRM: A double-blind, placebo-controlled phase III clinical
trial investigating the effect of nivolumab in patients with
relapsed mesothelioma: Study protocol for a randomised controlled
trial. Trials. 19(233)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fennell D, Ottensmeier C, Califano R,
Hanna G, Ewings S, Hill K, Wilding S, Danson S, Nye M, Steele N, et
al: Nivolumab versus placebo in relapsed malignant mesothelioma:
The CONFIRM phase 3 trial. J Thorac Oncol. 16
(Suppl)(S62)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fennell DA, Ewings S, Ottensmeier C,
Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L,
et al: Nivolumab versus placebo in patients with relapsed malignant
mesothelioma (CONFIRM): A multicentre, double-blind, randomised,
phase 3 trial. Lancet Oncol. 22:1530–1540. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Scherpereel A, Mazieres J, Greillier L,
Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette
C, Locatelli-Sanchez M, et al: Nivolumab or nivolumab plus
ipilimumab in patients with relapsed malignant pleural mesothelioma
(IFCT-1501 MAPS2): A multicentre, open-label, randomised,
non-comparative, phase 2 trial. Lancet Oncol. 20:239–253.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zalcman G, Mazieres J, Greillier L,
Brosseau S, Lantuejoul S, DO P, Bylicki O, Monnet I, Corre R,
Audigier-Valette C, et al: 2nd/3rd-line nivolumab vs nivo plus
ipilimumab in malignant pleural mesothelioma: long-term results of
IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression
(HPD). Ann Oncol. 30 (Suppl 5):v747–v755. 2019.
|
|
19
|
Disselhorst MJ, Quispel-Janssen J,
Lalezari F, Monkhost K, de Vries JF, van der Noort V, Hams E,
Burgers S and Baas P: Ipilimumab and nivolumab in the treatment of
recurrent malignant pleural mesothelioma (INITIATE): Results of a
prospective, single-arm, phase 2 trial. Lancet Respir Med.
7:260–270. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yap TA, Nakagawa K, Fujimoto N,
Kuribayashi K, Guren TK, Calabro L, Shapira-Frommer R, Gao B, Kao
S, Matos I, et al: Efficacy and safety of pembrolizumab in patients
with advanced mesothelioma in the open-label, single-arm, phase 2
KEYNOTE-158 study. Lancet Respir Med. 9:613–621. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Popat S, Curioni-Fontecedro A, Dafni U,
Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D,
et al: A multicentre randomised phase III trial comparing
pembrolizumab versus single-agent chemotherapy for advanced
pre-treated malignant pleural mesothelioma: The European thoracic
oncology platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol.
31:1734–1745. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Calabrò L, Morra A, Fonsatti E, Cutaia O,
Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M,
Mutti L and Maio M: Tremelimumab for patients with
chemotherapy-resistant advanced malignant mesothelioma: An
open-label, single-arm, phase 2 trial. Lancet Oncol. 14:1104–1111.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Calabrò L, Morra A, Fonsatti E, Cutaia O,
Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, et
al: Efficacy and safety of an intensified schedule of tremelimumab
for chemotherapy-resistant malignant mesothelioma: An open-label,
single-arm, phase 2 study. Lancet Resp Med. 3:301–309.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Maio M, Scherpereel A, Calabrò L, Aerts J,
Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, et
al: Tremelimumab as second-line or third-line treatment in relapsed
malignant mesothelioma (DETERMINE): A multicentre, international,
randomised, double-blind, placebo-controlled phase 2b trial. Lancet
Oncol. 18:1261–1273. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Calabrò L, Morra A, Giannarelli D, Amato
G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R,
Altomonte M, et al: Tremelimumab combined with durvalumab in
patients with mesothelioma (NIBIT-MESO-1): An open-label,
non-randomised, phase 2 study. Lancet Respir Med. 6:451–460.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Calabrò L, Rossi G, Morra A, Rosati C,
Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio
C, et al: Tremelimumab plus durvalumab retreatment and 4-year
outcomes in patients with mesothelioma: A follow-up of the
open-label, non randomised, phase 2 NIBIT-MESO-1 study. Lancet
Respir Med. 9:969–976. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Venkatraman D, Anderson A, Digumarthy S,
Lizotte PH and Awad MM: Phase 2 study of tremelimumab plus
durvalumab for previously-treated malignant pleural mesothelioma
(MPM). J Chin Oncol. 37 (Suppl 15):8549. 2019.
|
|
28
|
Masood R, Kundra A, Zhu S, Xia G, Scalia
P, Smith DL and Gill PS: Malignant mesothelioma growth inhibition
by agents that target the VEGF and VEGF-C autocrine loops. Int J
Cancer. 104:603–610. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zalcman G, Mazieres J, Margery J,
Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre
R, Monnet I, Gounant V, et al: Bevacizumab for newly diagnosed
pleural mesothelioma in the Mesothelioma Avastin Cisplatin
Pemetrexed Study (MAPS): A randomised, controlled, open-label,
phase 3 trial. Lancet. 387:1405–1414. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Roth GJ, Binder R, Colbatzky F, Dallinger
C, Schlenker-Herceg R, Hilberg F, Wollin SL and Kaiser R:
Nintedanib: From discovery to the clinic. J Med Chem. 58:1053–1063.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Grosso F, Steele N, Novello S, Nowak AK,
Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, et al:
Nintedanib plus pemetrexed/cisplatin in patients with malignant
pleural mesothelioma: Phase II results from the randomized,
placebo-controlled LUME-Meso Trial. J Clin Oncol. 35:3591–3600.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Scagliotti GV, Gaafar R, Nowak AK, Nakano
T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R,
Jakopovic M, et al: Nintedanib in combination with pemetrexed and
cisplatin for chemotherapy-naive patients with advanced malignant
pleural mesothelioma (LUME-Meso): A double-blind, randomised,
placebo-controlled phase 3 trial. Lancet Respir Med. 7:569–580.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tsao AS, Miao J, Wistuba II, Vogelzang NJ,
Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle
JG, et al: Phase II trial of cediranib in combination with
cisplatin and pemetrexed in chemotherapy-naïve patients with
unresectable malignant pleural mesothelioma (SWOG S0905). J Clin
Oncol. 37:2537–2547. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pinto C, Zucali PA, Pagano M, Grosso F,
Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo
F, et al: Gemcitabine with or without ramucirumab as second-line
treatment for malignant pleural mesothelioma (RAMES): A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet Oncol.
22:1438–1447. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hassan R, Kindler HL, Jahan T, Bazhenova
L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P,
et al: Phase II clinical trial of amatuximab, a chimeric
antimesothelin antibody with pemetrexed and cisplatin in advanced
unresectable pleural mesothelioma. Clin Cancer Res. 20:5927–5936.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hassan R, Sharon E, Thomas A, Zhang J,
Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K and
Pastan I: Phase 1 study of the antimesothelin immunotoxin SS1P in
combination with pemetrexed and cisplatin for front-line therapy of
pleural mesothelioma and correlation of tumor response with serum
mesothelin, megakaryocyte potentiating factor, and cancer antigen
125. Cancer. 120:3311–3319. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kindler HL, Novello S, Fennell DA,
Blumenschein G, Bearz A, Ceresoli G, Aerts J, Spicer J, Taylor P,
Taylor P, et al: Randomized phase II study of anetumab ravtansine
or vinorelbine in patients with malignant pleural mesothelioma. J
Thorac Oncol. 12(S1746)2017.
|
|
38
|
Sterner RC and Sterner RM: CAR-T cell
therapy: Current limitations and potential strategies. Blood Cancer
J. 11(69)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Castelletti L, Yeo D, van Zandwijk N and
Rasko JEJ: Anti-Mesothelin CAR T cell therapy for malignant
mesothelioma. Biomark Res. 9(11)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
NCT01583686: CAR T cell receptor
immunotherapy targeting mesothelin for patients with metastatic
cancer. https://clinicaltrials.gov/ct2/show/NCT01583686.
|
|
41
|
Maus MV, Haas AR, Beatty GL, Albelda SM,
Levine BL, Liu X, Zhao Y, Kalos M and June CH: T cells expressing
chimeric antigen receptors can cause anaphylaxis in humans. Cancer
Immunol Res. 1:26–31. 2013.PubMed/NCBI
|
|
42
|
Haas AR, Tanyi JL, O'Hara MH, Gladney WL,
Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et
al: Phase I study of lentiviral-transduced chimeric antigen
receptor-modified t cells recognizing mesothelin in advanced solid
cancers. Mol Ther. 27:1919–1929. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chintala NK, Restle D, Quach H, Saini J,
Bellis R, Offin M, Beattie J and Adusumilli PS: CAR T-cell therapy
for pleural mesothelioma: Rationale, preclinical development, and
clinical trials. Lung Cancer. 157:48–59. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Adusumilli PS, Zauderer MG, Rivière I,
Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala
NK, Halton E, et al: A Phase I trial of regional
mesothelin-targeted CAR T-cell therapy in patients with malignant
pleural disease, in combination with the anti-PD-1 agent
pembrolizumab. Cancer Discov. 11:2748–2763. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Popat S, Baas P, Faivre-Finn C, Girard N,
Nicholson AG, Nowak AK, Opitz I, Scherpereel A and Reck M: ESMO
Guidelines Committee Electronic address: simpleclinicalguidelines@esmo.org.
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 33:129–142.
2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
NCCN: Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) Malignant Pleural
Mesothelioma version 1.2022-December22, 2021. https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf.
|
|
47
|
Harber J, Kamata T, Pritchard C and
Fennell D: Matter of TIME: The tumor-immune microenvironment of
mesothelioma and implications for checkpoint blockade efficacy. J
Immunother Cancer. 9(e003032)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
van Zandwijk N, Clarke C, Henderson D,
Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen
M, et al: Guidelines for the diagnosis and treatment of malignant
pleural mesothelioma. J Thorac Dis. 5:E254–E307. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Brockwell NK, Alamgeer M, Kumar B,
Rivalland G, John T and Parker BS: Preliminary study highlights the
potential of immune checkpoint inhibitors in sarcomatoid
mesothelioma. Transl Lung Cancer Res. 9:639–645. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
NCT03762018: BEAT-meso: bevacizumab and
atezolizumab in malignant pleural mesothelioma. https://clinicaltrials.gov/ct2/show/NCT03762018.
|
